Developing Recombinant Anti Idiotypic Antibodies for PKPD and Immunogenicity Assays

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=ATgltK-dTVM

For more information, visit http://www.bio-rad.com/HuCAL-Anti-Dru... • Dr Achim Knappik, R D Group Manager at Bio-Rad Laboratories, describes the use of recombinant anti-idiotypic antibodies as specialized tools in the development of preclinical and clinical research assays for antibody drug development and how they are generated using proprietary HuCAL® recombinant antibody generation technology. Dr Knappik is the main inventor of the HuCAL technology. • He defines and illustrates the types of anti-drug antibodies and their applications in determining the levels of therapeutic antibody drugs in serum and the detection of patient immune response to the drug. The HuCAL PLATINUM® antibody library, containing ~45 billion members, is used with a guided selection method to generate high-affinity, anti-idiotypic antibodies (as Fabs) in just eight weeks; these monoclonal anti-idiotypic antibodies can be generated in large quantities with great consistency, and they can be further engineered to allow various assay designs. • The presentation concludes with a case study of the development of anti-trastuzumab (Herceptin®) antibodies and highlights a few of the company's anti-idiotypic antibody products. • Presenter: • Dr Achim Knappik • Head of Research and Development at AbD Serotec, a Bio-Rad company • AbD Serotec offers both an extensive range of primary and secondary antibodies and reagents as well as custom antibody generation services including anti-idiotypic antibodies. • https://www.bio-rad-antibodies.com/hu... • HuCAL® and HuCAL PLATINUM® are registered trademarks of MorphoSys AG. • Herceptin® is a registered trademark of Genentech Inc. USA.

#############################

New on site